<?xml version="1.0" encoding="UTF-8"?>
<p id="p0270">Parenteral formulations of oseltamivir and zanamivir and two new neuraminidase inhibitors (peramivir and laninamivir) are under investigation for the treatment of severe influenza. Convalescent plasmatherapy, monoclonal antibodies, and other forms of immunomodulation have shown promising results, warranting further evaluation in clinical trials.</p>
